Medical Professional Publications

Pharmacy and Therapeutics Committee Updates

(From the February 2017 Issue of MedStat)

The following actions were taken at the 1/5/17 Pharmacy & Therapeutics Committee meeting:

Medication stock lists were APPROVED for the Eye Clinic, IDC FACES Clinic, and Lewis Center Emergency Department

Pyxis overrides lists  were APPROVED for H12 and H9A (with one revision)

Pharmacy and Therapeutics Committee Goals for 2016 were revisited and new goals proposed for 2017

Ofloxacin 0.3% OTIC formulation was REMOVED from the Formulary. Instead, the ofloxacin 0.3% ophthalmic solution will be used for administration in the ear as was previously done during the OTIC product shortage.

Insulin glargine (Basaglar®) was ADDED to the Formulary; the monograph is posted on the P&T intranet site

Pancrealipase (Pertyze®) and perampanel (Fycompa®) were APPROVED for maintenance on the Formulary following 6-month reviews

Docusate oral liquid is available again – for informational purposes

Sulfamethoxazole/trimethoprim and Immune globulin IV administration guidelines were APPROVED

myChildren’s mobile app

iPhone and Android.

Download Today! »

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000